Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Ronan Swords(University of Miami), Jennifer S. Carew(University of Arizona), Ernest Medina(The University of Texas at San Antonio Health Science Center), Michael O’Dwyer(Ollscoil na Gaillimhe – University of Galway), Kelli Oberheu(The University of Texas at San Antonio Health Science Center), Francis J. Giles(National University of Ireland), Steffan T. Nawrocki(University of Arizona), James Garnsey(Millennium Engineering and Integration (United States)), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Peter G. Smith(Ollscoil na Gaillimhe – University of Galway), Kevin R. Kelly(Keck Hospital of USC)
Cited by 278
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951